Trial Profile
Phase I/II Study of Plitidepsin (Aplidin) in Combination with Cytarabine in Patients with Relapsed/Refractory Leukemia.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Plitidepsin (Primary) ; Cytarabine
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors PharmaMar
- 18 Apr 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 24 Oct 2008 New source identified and integrated (ClinicalTrials.gov record NCT00780143).
- 31 Mar 2008 New trial record.